


CAPTAF

Trial design: Patients with atrial fibrillation who failed at least one antiarrhythmic drug were randomized to catheter ablation versus optimized pharmacological therapy.



Results

- General health score at 12 months: mean change of 11 in the ablation group vs. mean change of 3.1 in the drug group (p = 0.0084)

Conclusions

- Among patients with paroxysmal or persistent atrial fibrillation who had failed at least one antiarrhythmic drug, catheter ablation was associated with improvement in quality of life compared with optimized drug therapy